皮肤性病指南

订阅

MedSci主页 / 所有栏目 / 皮肤性病指南

2021 BAD指南：慢性荨麻疹患者管理

2021-11-13 英国皮肤科医师协会 Br J Dermatol

皮肤疾病慢性荨麻疹

该指南的总体目标是为荨麻疹的管理提供最新的、基于证据的建议。

中文标题：

2021 BAD指南：慢性荨麻疹患者管理

英文标题：

British Association of Dermatologists guidelines for the management of people with chronic urticaria 2021

发布机构：

英国皮肤科医师协会

发布日期：

2021-11-13

简要介绍：

该指南的总体目标是为荨麻疹的管理提供最新的、基于证据的建议。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 BAD指南：慢性荨麻疹患者管理.pdf)] GetToolGuiderByIdResponse(projectId=1, id=e64281c00226e6cb, title=2021 BAD指南：慢性荨麻疹患者管理, enTitle=British Association of Dermatologists guidelines for the management of people with chronic urticaria 2021, guiderFrom=Br J Dermatol, authorId=0, author=, summary=该指南的总体目标是为荨麻疹的管理提供最新的、基于证据的建议。, cover=https://img.medsci.cn/20211119/1637333968039_1608702.jpg, journalId=0, articlesId=null, associationId=173, associationName=英国皮肤科医师协会, associationIntro=英国皮肤科医师学会（British Association of Dermatologists，BAD）成立于1920年，是一家由英国和爱尔兰皮肤科医生学者组成的专业组织。网站提供大量的临床指南，氨基丙名称分类，并明确标出5年内，5年以上及最近更新，可直接下载。拥有BJD及CED两本期刊。, copyright=0, guiderPublishedTime=Sat Nov 13 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #1c1d1e;">该指南的总体目标是为荨麻疹的管理提供最新的、基于证据的建议。</span></p>, tagList=[TagDto(tagId=27230, tagName=皮肤疾病), TagDto(tagId=100842, tagName=慢性荨麻疹)], categoryList=[CategoryDto(categoryId=39, categoryName=皮肤性病, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=100842, guiderKeyword=慢性荨麻疹, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=2, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3161, appHits=246, showAppHits=0, pcHits=739, showPcHits=2915, likes=2, shares=15, comments=17, approvalStatus=1, publishedTime=Fri Nov 19 23:24:39 CST 2021, publishedTimeString=2021-11-13, pcVisible=1, appVisible=1, editorId=1608702, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=4, createdBy=null, createdName=dajiong, createdTime=Fri Nov 19 22:59:18 CST 2021, updatedBy=1614372, updatedName=MedSciZeng, updatedTime=Thu Jan 04 06:19:19 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 BAD指南：慢性荨麻疹患者管理.pdf)])
2021 BAD指南：慢性荨麻疹患者管理.pdf
下载请点击：
评论区 (15)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1222625, encodeId=218b1222625ac, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91336389769, createdName=ms1000001927824594, createdTime=Thu May 26 17:09:39 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200802, encodeId=a1f012008027d, content=学习啦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d065548872, createdName=ms7000001433817342, createdTime=Wed Mar 09 09:11:31 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188609, encodeId=338f118860963, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201021/4cd86cce9ed54e988509d6d08e1df2f9/a10b9f2e66314ade887a789b03545465.jpg, createdBy=0dbb2416959, createdName=圆quanquan, createdTime=Thu Jan 27 16:14:19 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083640, encodeId=e398108364055, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b3e6411849, createdName=ms4000000068385678, createdTime=Thu Dec 23 20:04:28 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081744, encodeId=d7d11081e443c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b3e6411849, createdName=ms4000000068385678, createdTime=Sun Dec 19 11:02:45 CST 2021, time=2021-12-19, status=1, ipAttribution=)]
    2022-05-26 ms1000001927824594

    学习学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1222625, encodeId=218b1222625ac, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91336389769, createdName=ms1000001927824594, createdTime=Thu May 26 17:09:39 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200802, encodeId=a1f012008027d, content=学习啦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d065548872, createdName=ms7000001433817342, createdTime=Wed Mar 09 09:11:31 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188609, encodeId=338f118860963, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201021/4cd86cce9ed54e988509d6d08e1df2f9/a10b9f2e66314ade887a789b03545465.jpg, createdBy=0dbb2416959, createdName=圆quanquan, createdTime=Thu Jan 27 16:14:19 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083640, encodeId=e398108364055, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b3e6411849, createdName=ms4000000068385678, createdTime=Thu Dec 23 20:04:28 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081744, encodeId=d7d11081e443c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b3e6411849, createdName=ms4000000068385678, createdTime=Sun Dec 19 11:02:45 CST 2021, time=2021-12-19, status=1, ipAttribution=)]
    2022-03-09 ms7000001433817342

    学习啦

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1222625, encodeId=218b1222625ac, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91336389769, createdName=ms1000001927824594, createdTime=Thu May 26 17:09:39 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200802, encodeId=a1f012008027d, content=学习啦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d065548872, createdName=ms7000001433817342, createdTime=Wed Mar 09 09:11:31 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188609, encodeId=338f118860963, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201021/4cd86cce9ed54e988509d6d08e1df2f9/a10b9f2e66314ade887a789b03545465.jpg, createdBy=0dbb2416959, createdName=圆quanquan, createdTime=Thu Jan 27 16:14:19 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083640, encodeId=e398108364055, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b3e6411849, createdName=ms4000000068385678, createdTime=Thu Dec 23 20:04:28 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081744, encodeId=d7d11081e443c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b3e6411849, createdName=ms4000000068385678, createdTime=Sun Dec 19 11:02:45 CST 2021, time=2021-12-19, status=1, ipAttribution=)]
    2022-01-27 圆quanquan

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1222625, encodeId=218b1222625ac, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91336389769, createdName=ms1000001927824594, createdTime=Thu May 26 17:09:39 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200802, encodeId=a1f012008027d, content=学习啦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d065548872, createdName=ms7000001433817342, createdTime=Wed Mar 09 09:11:31 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188609, encodeId=338f118860963, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201021/4cd86cce9ed54e988509d6d08e1df2f9/a10b9f2e66314ade887a789b03545465.jpg, createdBy=0dbb2416959, createdName=圆quanquan, createdTime=Thu Jan 27 16:14:19 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083640, encodeId=e398108364055, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b3e6411849, createdName=ms4000000068385678, createdTime=Thu Dec 23 20:04:28 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081744, encodeId=d7d11081e443c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b3e6411849, createdName=ms4000000068385678, createdTime=Sun Dec 19 11:02:45 CST 2021, time=2021-12-19, status=1, ipAttribution=)]
    2021-12-23 ms4000000068385678

    学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1222625, encodeId=218b1222625ac, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91336389769, createdName=ms1000001927824594, createdTime=Thu May 26 17:09:39 CST 2022, time=2022-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200802, encodeId=a1f012008027d, content=学习啦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d065548872, createdName=ms7000001433817342, createdTime=Wed Mar 09 09:11:31 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188609, encodeId=338f118860963, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201021/4cd86cce9ed54e988509d6d08e1df2f9/a10b9f2e66314ade887a789b03545465.jpg, createdBy=0dbb2416959, createdName=圆quanquan, createdTime=Thu Jan 27 16:14:19 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083640, encodeId=e398108364055, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b3e6411849, createdName=ms4000000068385678, createdTime=Thu Dec 23 20:04:28 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1081744, encodeId=d7d11081e443c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b3e6411849, createdName=ms4000000068385678, createdTime=Sun Dec 19 11:02:45 CST 2021, time=2021-12-19, status=1, ipAttribution=)]
    2021-12-19 ms4000000068385678

    学习了

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

湿疹（湿疮）中医诊疗专家共识

中华中医药学会皮肤科分会 · 2021-10-30

2021 DAD 共识指南:大疱性表皮松解症的妊娠、分娩和后期护理建议

英国皮肤科医师协会(BAD,British Association of Dermatologists) · 2021-10-23

2021 NICE：苏金单抗治疗儿童和青少年中重度斑块状银屑病

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2021-10-07

常见红斑鳞屑性皮肤病的皮肤镜与组织病理学特征相关性专家共识( 2021)

中国医疗保健国际交流促进会皮肤科分会 · 2021-09-30

2016 BAD指南：皮肤疾病甲氨蝶呤处方用药的安全性和有效性

暂未更新 · 2016-07-01

拓展阅读

EADV：2014慢性荨麻疹管理指南

欧洲皮肤病与性病学会(EADV,European Academy of Dermatology and Venereology) · 2016-07-18

2021 BAD指南：慢性荨麻疹患者的管理

英国皮肤科医师协会(BAD,British Association of Dermatologists) · 2021-11-13

抗IgE疗法——奥马珠单抗治疗慢性荨麻疹专家共识

暂未更新 · 2021-12-28

慢性荨麻疹的疾病控制和反应评估的定义共识

Dermatology Department, Hospital del Mar, Institut Mar d'investigacions Mèdiques, Universitat Pompeu Fabra, Barcelona, Spain · 2022-01-01